Rhodium-Rhenium Alloy Nanozymes for Non-inflammatory Photothermal Therapy.

ACS Appl Mater Interfaces

Department of Radiation Oncology, The First Affiliated Hospital of USTC West District, Anhui Provincial Cancer Hospital, Hefei, Anhui 230031, People's Republic of China.

Published: May 2024

Analogous to thermal ablation techniques in clinical settings, cell necrosis induced during tumor photothermal therapy (PTT) can provoke an inflammatory response that is detrimental to the treatment of tumors. In this study, we employed a straightforward one-step liquid-phase reduction process to synthesize uniform RhRe nanozymes with an average hydrodynamic size of 41.7 nm for non-inflammatory photothermal therapy. The obtained RhRe nanozymes showed efficient near-infrared (NIR) light absorption for effective PTT, coupled with a remarkable capability to scavenge reactive oxygen species (ROS) for anti-inflammatory treatment. After laser irradiation, the 4T1 tumors were effectively ablated without obvious tumor recurrence within 14 days, along with no obvious increase in pro-inflammatory cytokine levels. Notably, these RhRe nanozymes demonstrated high biocompatibility with normal cells and tissues, both and , as evidenced by the lack of significant toxicity in female BALB/c mice treated with 10 mg/kg of RhRe nanozymes over a 14 day period. This research highlights RhRe alloy nanoparticles as bioactive nanozymes for non-inflammatory PTT in tumor therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsami.4c02550DOI Listing

Publication Analysis

Top Keywords

rhre nanozymes
16
photothermal therapy
12
nanozymes non-inflammatory
8
non-inflammatory photothermal
8
nanozymes
6
rhre
5
rhodium-rhenium alloy
4
alloy nanozymes
4
therapy
4
therapy analogous
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!